Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 103 of the 105 references it cites were found in a registry or an index.

Historical overview of the interleukin-6 family cytokine

Open access
Kang, Sujin, Narazaki, Masashi, Metwally, Hozaifa, Kishimoto, Tadamitsu · 2020 · Journal of Experimental Medicine

Abstract

Interleukin-6 (IL-6) has been identified as a 26-kD secreted protein that stimulates B cells to produce antibodies. Later, IL-6 was revealed to have various functions that overlap with other IL-6 family cytokines and use the common IL-6 signal transducer gp130. IL-6 stimulates cells through multiple pathways, using both membrane and soluble IL-6 receptors. As indicated by the expanding market for IL-6 inhibitors, it has become a primary therapeutic target among IL-6 family cytokines. Here, we revisit the discovery of IL-6; discuss insights regarding the roles of this family of cytokines; and highlight recent advances in our understanding of regulation of IL-6 expression.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1084/jem.20190347

Cites

103 of 103 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Receptor composition of IL-6 family cytokines. IL-6 family cytokines use gp130 to transduce their signals through gp130 homodimers or gp130-containing heterodimers. IL-6, IL-11, CNTF, CLCF1, and CLCF1/CLF require binding of their nonsignaling receptor to transduce signals. A new group of members (IL-27, IL-35, and IL-39) are heterodimeric cytokines: IL-27 consists of IL-27/p28 (IL-27α) and EBI3 (also known as IL-27β); in conformity to IL-12 containing IL-12p40 (IL-12α) and IL-12p35 (IL-12β), IL-23 (IL-23p19 [IL-23α] and IL-23p40 [IL-23β]), IL-35 (IL-23p40 and EBI3), and IL-39 (IL-23p19 and EBI3; Hunter, 2005; Ning-Wei, 2010; Wang et al., 2016a). These new members activate heterodimers of gp130. IL-6R exerts its biological effects via three different signaling modes. IL-6R expression is restricted to hepatocytes and several types of immune cells, whereas gp130 is ubiquitously expressed, reflecting the diverse roles of IL-6. In the classical mode of IL-6 signaling, the cytokine interacts with mIL-6R in cells that also express gp130 (Hunter and Jones, 2015). IL-6 also binds soluble IL-6R (sIL-6R), which is shed from cells following cleavage by ADAM metalloprotease 17 (ADAM17), and is also created by alternative mRNA splicing (Lust et al., 1992). The IL-6–sIL-6R complex binds to gp130, forming a dimer that initiates intracellular signaling, a process referred to as trans-signaling. Recently, a third mode of IL-6 signaling was identified: IL-6 trans-presentation (Heink et al., 2017). This mode is specific to dendritic cells, in which the IL-6–mIL-6R complex is presented to gp130 expressed on T cells to prime pathogenic Th17 cells. These alternative modes of IL-6 signaling contribute to multiple cellular processes.
Figure 1. Receptor composition of IL-6 family cytokines. IL-6 family cytokines use gp130 to transduce their signals through gp130 homodimers or gp130-containing heterodimers. IL-6, IL-11, CNTF, CLCF1, and CLCF1/CLF require binding of their nonsignaling receptor to transduce signals. A new group of members (IL-27, IL-35, and IL-39) are heterodimeric cytokines: IL-27 consists of IL-27/p28 (IL-27α) and EBI3 (also known as IL-27β); in conformity to IL-12 containing IL-12p40 (IL-12α) and IL-12p35 (IL-12β), IL-23 (IL-23p19 [IL-23α] and IL-23p40 [IL-23β]), IL-35 (IL-23p40 and EBI3), and IL-39 (IL-23p19 and EBI3; Hunter, 2005; Ning-Wei, 2010; Wang et al., 2016a). These new members activate heterodimers of gp130. IL-6R exerts its biological effects via three different signaling modes. IL-6R expression is restricted to hepatocytes and several types of immune cells, whereas gp130 is ubiquitously expressed, reflecting the diverse roles of IL-6. In the classical mode of IL-6 signaling, the cytokine interacts with mIL-6R in cells that also express gp130 (Hunter and Jones, 2015). IL-6 also binds soluble IL-6R (sIL-6R), which is shed from cells following cleavage by ADAM metalloprotease 17 (ADAM17), and is also created by alternative mRNA splicing (Lust et al., 1992). The IL-6–sIL-6R complex binds to gp130, forming a dimer that initiates intracellular signaling, a process referred to as trans-signaling. Recently, a third mode of IL-6 signaling was identified: IL-6 trans-presentation (Heink et al., 2017). This mode is specific to dendritic cells, in which the IL-6–mIL-6R complex is presented to gp130 expressed on T cells to prime pathogenic Th17 cells. These alternative modes of IL-6 signaling contribute to multiple cellular processes.CC BY-NC-SA · PubMed Central
Figure 2. Spatiotemporal regulation of the IL-6 gene. Infections activate TLR and cytokine receptor signaling. NF-κB and NF-IL6 act primarily as TFs in IL-6 mRNA transcription. Moreover, some miRNAs target IL-6 mRNA to dampen its expression. IL-6 mRNA is posttranscriptionally regulated in macrophages. Engagement of TLR4 promotes IL-6 and Arid5a transcription through distinct pathways. Arid5a stabilizes IL-6 mRNA and counteracts Regnase-1 activity. Zcchc11 stabilizes IL-6mRNA by uridylation of miR-26. TRAM, TRIF-related adaptor molecule; CRM1, chromosomal region maintenance 1.
Figure 2. Spatiotemporal regulation of the IL-6 gene. Infections activate TLR and cytokine receptor signaling. NF-κB and NF-IL6 act primarily as TFs in IL-6 mRNA transcription. Moreover, some miRNAs target IL-6 mRNA to dampen its expression. IL-6 mRNA is posttranscriptionally regulated in macrophages. Engagement of TLR4 promotes IL-6 and Arid5a transcription through distinct pathways. Arid5a stabilizes IL-6 mRNA and counteracts Regnase-1 activity. Zcchc11 stabilizes IL-6mRNA by uridylation of miR-26. TRAM, TRIF-related adaptor molecule; CRM1, chromosomal region maintenance 1.CC BY-NC-SA · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 105 references

Cited by

See all 389

Metadata

Authors
Kang, S., Narazaki, M., Metwally, H., & Kishimoto, T.
Affiliations
  • Immunology Frontier Research Center, The University of Osaka (JP)
  • The University of Osaka (JP)
Corresponding author
Kishimoto, Tadamitsu
Venue
Journal of Experimental Medicine
Published
2020-04-08
Volume
217
Issue
5
ISSN
  • 0022-1007 (ISSN-L)
  • 1540-9538
OpenAlex
W3014527183
Cited by
360
References
105
Citations by year
2026: 25 · 2025: 96 · 2024: 76 · 2023: 72 · 2022: 49 · 2021: 33 · 2020: 9
FWCI
4.37
Type
journal article
Language
en
Open access
Locations
  • The Journal of Experimental Medicine (publishedVersion, cc-by-nc-sa)
  • PubMed Central (publishedVersion, cc-by-nc-sa)
  • PubMed (publishedVersion)
Funders
  • Ministry of Education, Culture, Sports, Science and Technology (17K15722, 17K10002)
  • Astellas Foundation for Research on Metabolic Disorders
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Cytokine Signaling Pathways and Interactions
  • Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
  • Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
Keywords
interleukin-6, IL-6 family cytokines, gp130, IL-6 receptor, IL-6 signaling, IL-6 inhibitors, B cell antibody production
MeSH terms
Animals, Humans, Models, Biological, Mutation, Interleukin-6, Receptors, Interleukin-6, MicroRNAs, History, 20th Century, Genetic Pleiotropy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Historical overview of the interleukin-6 family cytokine. https://app.cochat.ai/papers/10.1084/jem.20190347
The paper
Kang, S., Narazaki, M., Metwally, H., & Kishimoto, T. (2020). Historical overview of the interleukin-6 family cytokine. Journal of Experimental Medicine. https://doi.org/10.1084/jem.20190347

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.